Note 5 - Business Segment Reporting

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

5. Business Segment Reporting

The Company manages its operations as

one

segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through

one

independent distributor, which is the only customer greater than

10%

of sales. The Company’s revenues by geographic region are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Consolidated Revenue:
United States	$	7,538	$	6,857	$	22,398	$	19,901
Brazil		3,385		3,114		10,013		9,833
Other		93		78		327		208
Total Revenue	$	11,016	$	10,049	$	32,738	$	29,942